

Global Liver Institute

FATTY LIVER DISEASE PORTFOLIO



A projected 1 in 4 people worldwide has fatty liver disease.

NIDDK, 2021

Global Liver Institute's (GLI) Fatty Liver Disease portfolio leads the fight against all stages of fatty liver disease worldwide, including MASH (metabolic dysfunction-associated steatotic hepatitis). GLI is dedicated to ensuring that the public and every patient are aware of this disease and have access to care to achieve prevention, early diagnosis, and effective treatment.



Fatty Liver Disease Council

The Fatty Liver Disease Council, *formerly the NASH Council*, comprising over **96 member organizations** – including patient advocacy groups, medical societies, and government agencies – champions fatty liver disease as a prominent public health concern. The Council advocates for patient priorities, amplifying the voice of the liver disease community in key regulatory and legislative realms.




Frank Anania, MD, Acting Director of the Division of Hepatology and Nutrition at the U.S. Food and Drug Administration, joined the Council's second semi-annual call

Scan and Visit Fatty Liver Disease Council page



2025 GOALS

- Lead robust advocacy initiatives to secure formal regulatory approval for NASH/MASH treatments, so patients have access to effective treatment choices
- Develop clinician education resources in collaboration with partners, with a focus on primary care specialists, to ensure accurate and timely screening, diagnosis, and treatment
- Collaborate with organizations to establish routine screening for fatty liver disease as a coexisting condition alongside diabetes and obesity to ensure timely assessments for at-risk individuals
- Develop and distribute support resources for veterans with or at risk of fatty liver disease in partnership with the Veterans Health Administration
- Ensure convenient, cost-effective patient access to medications and therapies



Jeff McIntyre, VP of liver health programs at GLI, presents findings from the NASH EL-PFDD at The Liver Meeting®, Boston, MA



GLI and H.E. Jesper Møller Sørensen, Ambassador of Denmark to the United States, co-hosted an event at the Ambassador's residence entitled "Obesity and the Future of Liver Health," Washington, DC

Achievements

- Patients shared their experiences at the inaugural NASH Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting for the U.S. FDA on November 4, 2021, to emphasize the urgency for NASH therapies.
- The U.S. NASH Action Plan 2022 Scorecard showcased significant strides made by various stakeholders, as outlined in the comprehensive U.S. NASH Action Plan.
- GLI and NASH patients addressed critical gaps in ICER's evaluation of NASH treatments on April 28, 2023, highlighting the need for comprehensive assessment.
- GLI spearheaded contributions from the liver advocacy community during the FDA Gastrointestinal Drugs Advisory Committee meeting on May 19, 2023, advocating for the application of obeticholic acid (OCA) as a viable NASH treatment.
- GLI collaborated on a cross-sectional survey on NASH in primary care and contributed to the resulting article, entitled "Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey."